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uterine bleeding, pelvic pain, and a number of other gynecological complications (3) , which are mainly due to the size and stiffness of the tumor primarily caused by the excessive deposition of ECM (4) . The current treatments are restricted to surgical hysterectomy, myomectomy, and/or hormonal agents that contribute substantially to health care costs of up to 34 billion dollars each year (5) . Because hysterectomy prevents future childbirth, finding effective therapeutic options is crucial for treating this disease, especially in younger women desiring to preserve their fertility.
The genetic background of uterine fibroids is diverse, indicating that there are multiple mutational events involved in tumor growth and development. Whole genome sequencing has identified four main genetic triggers of these tumors: mutations in the mediator complex subunit 12 (MED12); upregulation of high-mobility group AT-hook 2 (HMGA2); inactivation of fumarate hydratase (FH); or deletion of collagen, type IV a-5 (COL4A5) and collagen, type IV a-6 (COL4A6) (6) (7) (8) . MED12 mutations are the most common and occur at a higher frequency among patients with leiomyoma (9) (10) (11) . MED12 is a part of the mediator complex of transcriptional factors that regulate RNA polymerase II activity of targeted genes, which is required for cell growth, development, and differentiation (12) (13) (14) . It is therefore unsurprising that a genetic defect in the MED12 gene promotes abnormalities in the growth of cells and tumor progression (15, 16) . Fibroids also harbor alterations in epigenetic events, such as DNA methylation, histone modification, and microRNA expression, but their functions in leiomyogenesis are largely uncertain (17) .
Accumulating evidence shows that the most striking characteristic of uterine fibroid is the deposition of excessive amounts of ECM (18) (19) (20) (21) . ECM is a complex mixture of structural proteins comprised of collagens, proteoglycans, and glycoproteins, such as fibronectin and laminin, that function as a supportive structure to maintain three-dimensional tissue architecture. ECM actively participates in various biochemical signals, including cell adhesion, survival, proliferation, differentiation, and migration (22) . The ECM not only provides structural and functional support to cells but also governs cellular response and stimulates soluble mediators such as growth factors, hormones, and WNT signaling molecules via ligand-integrin interactions (23, 24) . Dysregulation in the ECM composition has been attributed to initiating tumor development and the progression of a range of diseases, including cancer and fibrosis (25) .
Despite the abundance and functional significance of ECM in uterine fibroids, no study has explored the global composition of the ECM proteome or "matrisome" of these tumors. Only recently, we and others have identified the set of common proteins (ECM-related and otherwise) that were either upregulated or downregulated in leiomyoma, irrespective of the MED12 mutation status and fibroid size (26, 27) . Because of the highly complex nature of total proteome, the proteins at a lower abundance, such as ECM-affiliated proteins and ECM regulators, are often missed by liquid chromatography-tandem mass spectrometry (LC-MS/ MS). To overcome these technical challenges, in this study, we performed the systematic enrichment method for ECM proteins followed by proteomic analyses of these enriched ECM fractions. By using this approach, we have described the ECM composition of uterine fibroid.
Materials and Methods

Patient samples and tissue collections
All human tissue collections and procedures were carried out after ethical approval from the Institutional Human Research Ethics Committee at the University of Newcastle (Callaghan, NSW, Australia). Multiple uterine fibroids of varying size and corresponding adjacent normal myometrium (ANM) tissues from each of the three patients (sample ID: ULM5, ULM20, and ULM22) were obtained from individuals (average age, 47 years) who underwent surgical hysterectomies at the John Hunter Hospital, Newcastle. The fibroids were sorted based on tumor size: small (,2 cm in diameter), medium (2.1 to 4 cm in diameter), and large (.4 cm in diameter). The ANM was taken at least 2 cm from adjacent fibroid tissue (28) . The suitability of the tissues obtained was evaluated and confirmed by a pathologist. The collected tissues were immediately transferred to the laboratory, washed with phosphate-buffered saline to eliminate excessive blood, snap-frozen, and stored in liquid nitrogen until further analysis (29) .
DNA extraction and MED12 mutation detection
Genomic DNA was isolated from 25 mg of fresh frozen fibroid or ANM tissues using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA). The purity and concentration of the extracted DNA were determined with a NanoDrop TM 2000/ 2000c spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). The primers designed for amplification of the MED12 exon 1 and exon 2 were previously described (10) . The purified PCR products of respective fibroid and ANM samples were sequenced on an ABI 3730xl Automatic DNA Analyzer (Applied Biosystems, Foster City, CA) (26) . Sequence chromatographs were verified for somatic mutations in exon 1 and exon 2 of MED12 using the Mutation Surveyor software (Softgenetics, State College, PA).
Fibroid and ANM tissue decellularization and ECM enrichment
To achieve the enrichment of ECM protein of genetically annotated fibroids and ANM, 80 to 100 mg of each tissue sample were dissected into smaller pieces and resuspended in the cytosolic buffer of the CNMCS compartment protein extraction kit (Millipore, Temecula, CA) according to the manufacturer's instructions (Table 1) . The samples were then homogenized with a BeadBug homogenizer (Benchmark Scientific, Edison, NJ) until the tissue was completely disrupted. The homogenates were subjected to incubations in a series of buffers to deplete intracellular proteins (cytosolic, nuclear, membrane and cytoskeletal; Table 1 ), leaving a final insoluble pellet enriched for ECM proteins (30, 31) . The efficiency and expression of ECM protein enrichment were validated by Western blotting using the following primary antibodies: rabbit anti-collagen I (1:5000; Millipore; AB745; RRID: AB_11213694) and mouse anti-b-actin (1:4000; Developmental Studies Hybridoma Bank; JLA20; RRID: AB_528068).
ECM protein digestion into peptides
ECM-enriched insoluble pellets from the three fibroids (small, medium, and large) and one ANM tissue from each of the three patients (n = 12 tissue samples; 9 fibroids and 3 ANM) were dissolved in 8 M urea and reduced with 10 mM dithiothreitol at 37°C for 2 hours, followed by alkylation with 25 mM iodoacetamide (Sigma-Aldrich, St. Louis, MO). Samples were incubated in the dark at room temperature for 30 minutes. Protein samples were then deglycosylated with PNGaseF (New England Biolabs, Ipswich, MA) and digested with endopeptidase Lys-C (Wako, Osaka, Japan) and mass spectrometrygrade trypsin (Promega, Madison, WI) overnight at 37°C (30, 31) . Peptide solutions were acidified with 50% trifluoroacetic acid, desalted using the Pierce TM C18 Spin Columns (Thermo Fisher Scientific, Rockford, IL), and eluted with 70% acetonitrile, 0.1% trifluoroacetic acid. Peptide concentrations were determined using a Qubit 2.0 Fluorometer assay (Invitrogen, Eugene, OR).
Mass spectrometry and protein identification
The separation of peptides was carried out using nanoflow liquid chromatography (Thermo Dionex, Ultimate 3000 RSLCnano; Thermo Fisher Scientific, Waltham, MA). Equal volumes of ;100 ng of each peptide sample were loaded through a trapping column for preconcentration [Acclaim Pepmap100 (20 3 0.075 mm, 3 mm C18); Thermo Fisher Scientific, Waltham, MA] and then resolved in the EASYSpray C18 column (500 3 0.075 mm inner diameter, PepMap 2 mm) at a constant flow rate of 250 nL/min. Runs were performed with solvent A (containing 0.1% formic acid in high-performance liquid chromatography water) under 120-minute linear gradient from 2% to 35% of solvent B (containing 80% ACN combined with 0.1% formic acid). The eluted peptides were directly analyzed using Q-Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) with a nano-electrospray emitter at the sampling region as described (26) . The raw tandem mass spectrometry (MS/MS) data were processed with the Proteome Discoverer software package (version 2.0.0.802; Thermo Fisher Scientific). A database search was accomplished using the UniProt Human reference proteome database (updated to October 2016) with standard settings: 10 ppm mass tolerance for precursor ions and 0.02 Da for fragment-ion mass tolerance; enzyme, trypsin; allowed for up to two missed cleavages; allowed variable modifications were acetylation and methylation of lysine, deamidation of asparagine and glutamine, Scarbamidomethylation of cysteine residues, and oxidation on methionine and phosphorylation on serine, threonine, and tyrosine. A false discovery rate (FDR) analysis using Proteome Discoverer was performed on all searches. Proteins and peptides identified with a local FDR of ,1% were included for further analysis. Proteins represented by at least two unique peptides were included in the analysis and subsequently screened using an in silico matrisome list (http://web.mit.edu/ hyneslab/matrisome/) to characterize the identified proteins as being of ECM origin or not (30) . Data were analyzed using Gitools 2.3.1 software to generate heat maps and Venny 2.1.0 (BioinfoGP) to create Venn diagrams, illustrating the number of shared and differentially expressed matrisome proteins across the fibroid size range and ANM. We set the following thresholds for changes in protein expression: changes .1.5-fold were considered upregulation, and changes ,0.66-fold were considered downregulation.
Matrisome protein-protein interaction network analysis
The list of identified matrisome proteins across fibroid size range and ANM from the three patients were mapped onto Search Tool for Retrieval of Interacting Genes/Proteins (STRING) Version 10.5 database (https://string-db.org/) to identify the interactions between known proteins and predicted proteins. Our results in this database were obtained from the following settings: network edges, including interaction evidence; active interaction sources, allowed text mining, experiments, databases, coexpression, neighborhood, gene fusion, and co-occurrence; interaction score with high confidence (0.700); maximum number of interactors was none. Each node color represents protein involvement in specific KEGG pathways in uterine fibroids.
Western blotting
Fibroid or ANM tissue extracts were homogenized in radioimmunoprecipitation assay buffer [25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS], and protein extracts (30 mg) were subjected to SDS-PAGE (10% Mini-PROTEAN ® TGX™ Gels, Bio-Rad, Hercules, CA). SDS-PAGE was used to separate protein homogenates, which were transferred to a nitrocellulose membrane (Amersham TM Protran TM NC 45; 0.45 mM; Sigma-Aldrich). Membranes were blocked for 1 hour in 5% milk (weight/volume ratio) in Trisbuffered saline containing 0.1% Tween-20 (TBST), followed by incubation with rabbit anti-collagen, anti-fibronectin (1:1000; Abcam; ab32419; RRID: AB_732379), or anti-actin overnight at 4°C. After three washes in 13 TBST, membranes were incubated with secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 hour at room temperature. Membranes were thoroughly washed three times in 13 TBST before imaging. Reactive protein was detected using an LAS-3000 imager (Fujifilm, Tokyo, Japan). Densitometric analysis of the Western blot was performed using ImageJ plugin software (National Institutes of Health, Bethesda, MD), and all proteins were quantified relative to the loading control.
Statistical analysis
Data were analyzed and graphed with GraphPad Prism 6.0 (GraphPad Software, San Diego, CA). Statistical significance was calculated using Student t test; P values ,0.05 were considered statistically significant. For proteomic data analysis, the Student t test value comparing the matrisome protein expression differences between the ANM and fibroid across patients was corrected to P values using the Benjamini-Hochberg method (32) .
Results
ECM protein enrichment from genetically annotated uterine fibroids and ANM tissues
We examined the MED12 genetic status of the uterine fibroids and corresponding ANM by Sanger sequencing prior to the ECM protein isolation procedure. We identified missense mutations affecting codons 41 and 44 in exon 2 of MED12 (including V41Q, G44V, G44C, and G44D mutations) within various-size fibroid and did not observe any mutations in the ANM samples ( Table 2 ; Supplemental Fig. 1 ). All genetic alterations detected in this study were known mutational hotspots in MED12. We then performed an ECM enrichment process on the genetically annotated uterine fibroids (small, medium, and large) and on the ANM tissue sample from each of the three patients for subsequent analysis by LC-MS/MS (n = 3 normal, n = 9 fibroids). This process depleted other cellular proteins from the cytosol, the nucleus, the membrane, and the cytoskeleton, leaving behind an insoluble fraction that contains the ECM (30) . Increased expression of collagen-I confirmed the enrichment of ECM fraction of fibroids and ANM [ Fig. 1(A) ].
Characterization of the ECM of genetically annotated uterine fibroids and ANM tissues
To investigate the composition of the ECM-enriched fractions achieved after the decellularization process, we digested the ECM proteins into peptides and performed proteomic analysis by LC-MS/MS to identify ECM peptides and proteins. From the three patients, a combined total of 1010, 947, 1130, and 1224 proteins were identified in ANM and small, medium, and large fibroids, respectively [ Table 2 ; Fig. 1 We next characterized the 126 ECM proteins into matrisome subcategories within the core matrisome (i.e., ECM glycoproteins, collagens, and proteoglycans) (Fig. 2) and matrisomeassociated proteins (i.e., ECM-affiliated proteins, ECM regulators, and secreted factors) (Fig. 3) . Altogether, 81 out of 126 (64%) ECM proteins from three different patients were detected as core matrisomal proteins that contained 51% ECM glycoproteins (41/81), 37% collagens (30/81), and 12% proteoglycans (10/81) in the small fibroids [ Table 2 ; Fig. 1(B) and 1(C) ]. The remaining 45 (36%) ECM proteins were classified as matrisomeassociated proteins, which were comprised of 28% ECM-affiliated proteins (13/45), 60% ECM regulators (27/45), and 11% secreted factors (5/45) [ Table 2 ; Fig. 1(B) and 1(C) ]. Comprehensive data (including accession number, gene ID, number of unique peptides, coverage, fold change in abundance of fibroid compared with ANM, and the P , 0.05 adjusted by the BenjaminiHochberg method) of the identified ECM proteins found in small, medium, and large fibroids from the three patients and sorted according to the matrisome categories are listed in Supplemental Table 1 .
We next defined the matrisome signature enriched in the medium-size fibroids and detected a total of 126 ECM proteins in the three patients [ Table 2 ; Fig. 1 (B) and 1(D)]. More specifically, 20 of these ECM proteins [dentin sialophosphoprotein (DSPP), ECM protein 2 (ECM2), MXRA5, THBS4, TNN, COL10A1, COL19A1, collagen type XXIII a-1 (COL23A1), COL4A5, keratocan (KERA), C1QBP, PLXNB3, SDC2, ADAMTS5, ADAMTS12, PLOD1, PLOD3, host cell factor 1 (HCFC1), WNT16, and WNT10A] were not identified in ANM [ Fig. 1(D), Fig. 2, and Fig. 3] . A total of 126 ECM proteins enriched in the medium-size fibroids were categorized into matrisome subcategories: core matrisomal proteins (82/126; 65%) consisting of 50% ECM glycoproteins (41/82), 37% collagens (30/ 82), and 13% proteoglycans (11/82) and matrisomeassociated proteins (44/126; 35%) made up of 30% ECM-affiliated proteins (13/44), 59% ECM regulators (26/44), and 11% secreted factors (5/44) [ Table 2 ; Fig. 1(B) and 1(C)] .
Analysis of the large-size fibroid matrisome identified a total of 130 ECM proteins [ Table 2 ; Fig. 1 Fig. 2, and Fig. 3 Table 2 ; Fig. 1(B) and  1(D) ]. In addition to the fibroid matrisome profile (small, medium, and large), we have successfully characterized ECM proteins in ANM. Altogether, 108 ECM proteins were detected from the three samples from patients with ANM and categorized according to core matrisomal proteins (72/108; 67%), which revealed 50% ECM glycoproteins (36/72), 36% collagens (26/72), and 14% proteoglycans (10/72) and matrisome-associated proteins (36/108; 33%) containing 28% ECM-affiliated proteins (10/36), 61% ECM-regulators (22/36), and 11% secreted factors (4/36) [ Table 2 ; Fig. 1(B)-1(D) ].
Periostin, tenascin, collagen type III a-1, collagen type XXIV a-1, and asporin are significantly upregulated ECM proteins during early stages of uterine leiomyogenesis
One of the objectives of the study was to find regulated matrisome proteins associated with uterine fibroids (MED12 mutation positive and MED12 mutation negative). Figures 2 and 3 show the heat map illustration of upregulated and downregulated matrisome proteins. In brief, we used peptide intensity of digested proteins to determine relative protein amounts at the MS level. We then determined the ratio of fold-change by measuring the MS intensities of peptide abundance from each fibroid size range vs the corresponding ANM sample. We classified a ratio .1.5 to indicate that a protein is upregulated compared with the matched ANM sample and a ratio ,0.66 to indicate that a protein is downregulated compared with the ANM sample. The P values were calculated by Student t test comparing the protein expression differences between ANM and fibroid across the three patients and adjusted for multiple testing by the Benjamini-Hochberg procedure ( Figs. 2 and 3 ; Supplemental Table 1 ). Because small-sized fibroids are indicative of early-stage uterine leiomyogenesis, we focused on the top five significant upregulated proteins: periostin (POSTN, 14.95-fold change, P = 0.0117), tenascin (TNC, 4.69-fold change, P = 0.0151), collagen type III a-1 (COL3A1, 4.53-fold change, P = 0.0236), collagen type XXIV a-1 (COL24A1, 10.53-fold change, P = 0.0089), and asporin (ASPN, 3.46-fold change, P = 0.000097) (Figs. 2 and 3 ; Supplemental Table 1 ). These proteins represent potential drug targets against uterine leiomyogenesis.
We also compared the protein expression patterns in medium and large fibroids vs the corresponding small fibroids in three patients (Fig. 4) . We applied our strict selection criteria of ECM proteins in small fibroids (i.e., only proteins existing across the three patients and containing at least two unique peptides were included in the proteomic analysis). Matrisome analysis of small-vs medium-sized fibroids revealed that 6 out 106 ECM proteins were significantly downregulated in medium fibroids as compared with small fibroids regardless of MED12 mutation status [collagen type XXVIII a-1 (COL28A1; P = 0.0001), collagen type IV a-2 (COL4A2; P = 0.007), stromal cell-derived factor 1 (CXCL12; P = 0.0001), fibrillin-1 (FBN1; P = 0.008), laminin subunit a-5 (LAMA5; P = 0.0004), and microfibril-associated glycoprotein 4 (MFAP4; P = 0.0004)] (Fig. 4 ; Supplemental Table 2 ). For matrisome analysis of large fibroids, we detected six ECM proteins that were statistically significant in their expression when compared with small fibroids. Specifically, one out of these six proteins [annexin A4 (ANXA4; P = 0.03)] is significantly upregulated in large fibroids compared with small fibroids. The remaining five ECM proteins [COL24A1 (P = 0.0006), CXCL12 (P = 0.00008), latent-transforming growth factor b-binding protein 1 (LTBP1; P = 0.00003), MFAP4 (P = 0.00008), and prolargin (PRELP; P = 0.008)] were significantly downregulated (Fig. 4) .
Because we have previously validated the high expression of POSTN (26) and TNC (33) in fibroids, we used Western blotting to analyze collagen I and fibronectin expression in eight patients (total, n = 16) (Fig. 5) . The Western blotting results revealed higher levels of collagen I and fibronectin in small fibroids compared with corresponding ANM in eight patients ( Fig. 5 ; eight ANM vs eight fibroids; collagen I, P = 0.04; fibronectin, P = 0.08).
String analysis revealed ECM receptor and focal adhesion interactions, phosphatidylinositol 3-kinase-protein kinase B signaling, and other pathways related to cancer Based on our proteomic results, we mapped out the list of matrisome proteins across the fibroid size range (n = 9 fibroids) using the STRING Version 10.5 database to identify the associated protein-protein interaction and pathway analysis. These analyses highlighted a number of important protein networks, including ECM-receptor and focal adhesion interactions, phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) signaling, small cell lung cancer, pathways in cancer, and proteoglycans in cancer (Fig. 6) . The data set of 11 pathways (including pathway ID, FDR, and matching protein IDs) significantly enriched in uterine fibroids are listed in Supplemental Table 3 . The involvement of these matrisome protein networks in fibroids suggested that each one of these ECM proteins is likely to influence one another to promote and increase ECM deposition in fibroids.
Discussion
Uterine fibroids afflict millions of women worldwide each year, and the current treatment opportunities are limited and ineffective at retaining the reproductive potential of young patients. Despite causing impaired fertility, substantial health care cost, obstetric complications, and gynecological morbidity, the precise etiology of uterine fibroids remains unknown. One interesting histopathological feature of fibroids is the excess accumulation and production of ECM proteins, such as collagens, fibronectin, and proteoglycans (23, 34) . These ECM components enhanced the capacity of ECM deposition as well as the size and stiffness of the tumor, which are more likely to cause bulk symptoms associated with fibroids (23) . The overexpression of ECM increases mechanical stress on cells, which activates Rho-dependent signaling (4, 35, 36) . The activation of this solid-state signaling and alterations in ECM may contribute to fibroid development (4, 35, 36) . Considering that fibroids are characterized by a copious amount of ECM, antifibrotic agents could be an emerging target to dissolve ECM for the treatment of uterine fibroids. Recent findings suggested that an increase in the ECM-degrading enzyme collagenase activity led to degradation of the collagen matrix (37, 38) . For a more comprehensive assessment of targeting abnormal ECM in uterine fibroids, we need to define the composition of the ECM proteome in these tumors. Previous proteomic approaches examining the whole proteome were limited because low-abundance proteins, such as matrisomeassociated proteins, are undetectable by LC-MS/MS due to the highly complex nature of the total protein extract. By using a systematic ECM enrichment procedure, we were able to enrich and identify the lower-abundance ECM-associated proteins.
We report here the characterization of the ECM composition of each genetically annotated fibroid size range (small, medium, and large) and ANM tissue and expression changes at the protein level between samples. Most important, our approach takes into account interpatient and intrapatient variations that are related to the wide range of fibroid types. By using our approach of analyzing different-size fibroids from the same patient, any changes that are observed can be attributed to the disease state and are not a consequence of patient-to-patient variation. Genetic screening of MED12 mutations in uterine fibroids and corresponding ANM were carried out by Sanger sequencing before the ECM enrichment procedure. Our genetic data (Table 2 ; Supplemental Fig. 1 ) are consistent with other studies (10, 39) indicating that the mutations in exon 2 of the MED12 are the most commonly reported genetic anomalies in fibroids. We performed the ECM enrichment process on the genetically annotated uterine fibroids (small, medium, and large) and on an ANM tissue sample from each of the three patients prior to proteomic analysis. This allowed us to study whether MED12 mutation and fibroid size affect ECM characterization and expression patterns.
By using a standard ECM proteomic pipeline, we were able to provide a detailed characterization of the composition of ECM derived from ANM vs fibroids. Our analysis revealed a combined total of 108, 126, 126, and 130 unique ECM and ECM-associated proteins identified in ANM and in small, medium, and large fibroids, respectively. The major proportion of fibroid ECM proteins belongs to the core matrisome that includes glycoproteins, collagens, and proteoglycans [ Fig. 1 (B) and 1(C) and Fig. 2 ). The proteins of the core matrisome are known to contribute to the molecular architecture and mechanical properties to the ECM and participate in cell adhesion and signaling predominantly through integrin interaction (40) . Collagens, fibronectin, laminins, and proteoglycans have also been reported to be elevated in fibroids compared with ANM (36, 41, 42) . Considering small-sized fibroids represent the earliest stages of fibroid development, our data captured some of the most abundant and important upregulated core matrisome proteins in small fibroids. These proteins are POSTN and TNC representing ECM glycoproteins, COL3A1 and COL24A1 from the collagen family, and proteoglycan ASPN (Fig. 2) . POSTN was one of the most significantly upregulated proteins, with an average of 14.95-fold higher expression in fibroids than ANM ( Fig. 2 ; Supplemental Table 1 ). This is in agreement with our previous finding that increased expression of the ECM protein periostin is a hallmark of uterine fibroids regardless of MED12 mutations (26) . These ECM proteins (POSTN, TNC, COL3A1, COL24A1, and ASPN) represent potential drug targets to hinder the growth and development of fibroids.
The growth of fibroids has also been previously linked with elevated expression of genes involved in the WNT pathway, such as b-catenin (43). Our proteomic data revealed that three WNT proteins (WNT16, WNT8B, and WNT10A) exist in tumors but not in ANM control tissue. The roles of these specific WNT proteins are not clear, but it is possible that they activate certain signaling processes in tumor cells that enhance the survival and fitness of the tumor cells. Consistently, suppression of WNT signaling has been shown to retard the growth of fibroid cells (44) .
In summary, our study explored the detailed composition and origin of the fibroid ECM at the protein level and highlights many proteins of potential importance for tumor growth and progression. We believe that these data sets will be useful in further exploring the composition of the ECM and provide a unique opportunity to develop approaches to counter overproduction of ECM in fibroids, thereby reducing the morbidity, mortality, and economic burden associated with the condition.
